Medialis Intelligent End-to-End Medical Affairs
Medialis has a long track record in the developing bespoke medical plans for a range of medicines from rare diseases to vaccines…
All medical planning requires a degree of creative thinking.scroll down
All medical planning requires a degree of creative thinking.
Often, this is informed by a traditional situational analysis and SWOT, tools that will be familiar to brand teams.
Given the critical nature of key evidence careful consideration must be given to the type of evidence to generate and how it will be used.
Medialis works closely with the organisation’s medical, marketing and market access functions to agree on critical success factors and works with them to generate aspirational statements that need to support the generation of key evidence.
Multi-stakeholder European Medical Plan Generation
Medialis is a medical affairs consultancy servicing the pharmaceutical industry. Unlike some other agencies, we are proactive, not reactive or one-dimensional – if you need it, we can do it.
We will generate and support your product’s pipeline:
- Create a cross-functionally agreed European Pharma Medical Affairs Plan for 2020-22
- Ensure internal multidisciplinary engagement to guarantee the medical plan meets all stakeholders’ need
- Plan to be aligned in order of: Strategic objectives, Critical Success Factors and aspirational statements on mAb’s and the disease (currently not substantiated by evidence)
- MEDIALIS will define RWE ‘assets’ to be generated support these statements and aligned CSFs
Delivering Real World Evidence... because clinical trials only get you so far.
Medialis recognises the challenges of in-house delivery of medical affairs projects, offering a complete Intelligent End-to-End Medical Affairs delivery vehicle.
Medialis ensures the right strategic asset is generated for the right reason...communicated in the right way.
We can help you... send us an email to [email protected]
Jandhyala method 
A novel group awareness and consensus method (Jandhyala 2020) is used to develop the medical plan. This engages all the internal stakeholders relevant to the commercialisation of a medicine ensuring all external stakeholders’ needs are recognised and accommodated in the development of the critical success factors and aspirational statements.
 (2020) A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning, Current Medical Research and Opinion,
Engagements 1 & 3 will utilise the full method (awareness and consensus stages). Engagement 2 will simply execute the consensus stage.